Clinical Trials Logo

Hepatitis A clinical trials

View clinical trials related to Hepatitis A.

Filter by:

NCT ID: NCT03222583 Completed - Clinical trials for Hepatitis C Virus (HCV)

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection

VOYAGE-1
Start date: October 4, 2017
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in non-cirrhotic chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with or without human immunodeficiency virus (HIV) co-infection who are HCV treatment-naïve or treatment-experienced with interferon (IFN) with or without ribavirin (RBV), OR sofosbuvir with RBV with or without IFN.

NCT ID: NCT03219957 Completed - Hepatitis C Clinical Trials

Study of AT-527 in Healthy and HCV-Infected Subjects

Start date: July 6, 2017
Phase: Phase 1
Study type: Interventional

This study has multiple parts. It will assess the safety, tolerability and pharmacokinetics (PK) of AT-527 in healthy subjects and subjects infected with hepatitis C virus (HCV). In addition, the study will assess the antiviral activity of AT-527 in subjects infected with HCV.

NCT ID: NCT03219216 Completed - Clinical trials for Hepatitis C Virus (HCV)

A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection

Start date: June 6, 2018
Phase: Phase 3
Study type: Interventional

This was a Phase 3, open-label, multicenter study to evaluate the efficacy and safety of glecaprevir (GLE)/pibrentasvir (PIB) for an 8 or 12-week treatment duration in adults in Brazil with chronic hepatitis C virus (HCV) genotype (GT) 1 to GT6 infection, without cirrhosis or with compensated cirrhosis, who were HCV treatment-naïve.

NCT ID: NCT03215732 Completed - Chronic Hepatitis b Clinical Trials

Cross Sectional Survey on the Burden and Impacts of Chronic Hepatitis B in the Rural Area of Niakhar, Senegal

AMBASS
Start date: October 19, 2017
Phase:
Study type: Observational

This study aims at estimating the prevalence of chronic hepatitis B virus (HBV) infection in rural Senegal (area of Niakhar) and at evaluating the associated burden in terms of both health-related and socio-economic consequences.

NCT ID: NCT03212521 Completed - Clinical trials for Hepatitis C Virus (HCV)

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

Start date: August 7, 2017
Phase: Phase 3
Study type: Interventional

A study to evaluate the efficacy and safety of glecaprevir(GLE)/pibrentasvir(PIB) in treatment-naïve participants with chronic hepatitis C virus (HCV) genotypes 1-6 infection and with an aspartate aminotransferase to platelet ratio index (APRI) of less than or equal to 1.

NCT ID: NCT03201718 Completed - Clinical trials for Hepatitis C Virus (HCV)

A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs

HCV PMS
Start date: August 17, 2017
Phase:
Study type: Observational

Post-marketing surveillance study to evaluate the real world safety and effectiveness of Viekira/ Exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) administered under a normal, routine treatment practice by Korean patients with Hepatitis C.

NCT ID: NCT03200184 Completed - Hepatitis C Clinical Trials

Sofosbuvir and Daclatasvir in Treating Hepatitis C, A Study on 1000 Patients

SD1000
Start date: September 1, 2016
Phase: Phase 4
Study type: Interventional

The fixed-dose combination of sofosbuvir and daclatasvir in a single pill is being used for the treatment of hepatitis C in Iran. In this study the efficacy of this combination is evaluated in 1000 patient with hepatitis C.

NCT ID: NCT03200171 Completed - Hepatitis C Clinical Trials

Effect of DAAs on Behavior of HCC in HCV Patients

Start date: February 10, 2018
Phase:
Study type: Observational

Investigators aim to study the effect of direct acting antiviral agents (DAAs) on behavior of hepatocellular carcinoma (HCC) and overall survival in patients with chronic hepatitis C (CHC).

NCT ID: NCT03188276 Completed - Chronic Hepatitis C Clinical Trials

The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAs

Start date: February 1, 2016
Phase: Early Phase 1
Study type: Interventional

Hepatitis C virus (HCV) infection is easy to chronic and can progress to cirrhosis and liver cancer. Direct-acting antiviral treatment can significantly improve the prognosis of the disease and the efficacy is seemingly not affected by a variety of viral factors. In addition, direct-acting antiviral agents therapy may affect the transformation of the immune cells and ameliorate the host immune status consequently. This study mainly investigated the relationship between Direct Acting Antiviral Treatment effect and the functional activity of myeloid-derived suppressor cells (MDSCs) and natural killer cells (NK cells) in Chronic Hepatitis C.

NCT ID: NCT03186235 Completed - Hepatitis C Clinical Trials

T Regulatory Cells in Hepatitis c Infected Patients

Start date: July 1, 2018
Phase:
Study type: Observational

Chronic hepatitis C infection is a global worldwide health problem with an increasing burden year-by-year, particularly in areas with a high endemicity like Egypt . The World Health Organization estimates that approximately 200 million people worldwide are infected with hepatitis c virus. In Egypt, it was estimated that 15 % of Egyptians have serologic evidence of hepatitis C viral infection .